Volume 14 - Issue 2 - February, 2002

Unusual Mechanism of Coronary Perforation During PTCA

Paolo Esente, MD, Ronald Caputo, MD, Carlton Levy, Alessandro Giambartolemei, MD, Alan Simons, MD, Mark Reger, MD, Gary Walford, MD

Case Description. A 79-year-old female with history of hypertension, hyperlipidemia and peripheral vascular disease underwent successful direct stenting of her left anterior descending coronary artery on March 15, 2000 in the setting of unstable angina, utilizing a 3.0 x 15 mm Medtronic/AVE S670 stent deployed at 16 atmospheres (Medtronic-AVE, Santa Clara, California). Follow-up coronary angiography on September 1, 2000 for recurrent angina revealed angiographically significant in-stent focal restenosis (Figure 1). Intravascular ultrasound (IVUS) was performed to address the possible un...

Facilitated Percutaneous Intervention Following Combination Therapy with Reteplase and Abciximab for Acute Myocardial Infarcti

Barry S. Weinstock, MD

Case Report. R.C. is a 45-year-old white male who presented to the Emergency Department at Largo Medical Center with a massive acute anterior wall myocardial infarction (MI). The patient denied any prior history of coronary artery disease (CAD), but admitted to intermittent chest pain over the preceding week. He had a moderately severe episode of chest pain lasting nearly 2 hours the evening before this event but the symptoms resolved spontaneously and he attributed the symptoms to indigestion. He was previously treated by his primary care physician with statin therapy for “mild” hy...

Prophylactic Abciximab in Elective Coronary Stenting: Results of a Randomized Trial

Corrado Tamburino, MD, Giovanni Russo, MD, Antonino Nicosia, MD,
Alfredo R. Galassi, MD, Rosario Foti, MD, V. Scriffignano, DSc, *Dean J. Kereiakes, MD, Giuseppe Giuffrida, MD

Recent large randomized trials have shown that abciximab [a potent inhibitor of platelet aggregation via glycoprotein (GP) IIb/IIIa blockade] is a safe and effective drug in reducing the incidence of death, myocardial infarction and the need for urgent revascularization after percutaneous transluminal coronary balloon angioplasty or coronary stent deployment.1,2 Furthermore, the use of abciximab in “high-risk” coronary angioplasty was associated with a significant reduction in target lesion revascularization at 6-month3 and 3-year follow-up.4
Intracoronary stents have been demonstrated to...

Editorial Staff
  • Executive Officer
    Laurie Gustafson
  • Production
    Elizabeth Vasil
  • National Account Manager
    Jeff Benson
  • Senior Account Director
    Carson McGarrity
  • Special Projects Editor
    Amanda Wright
Editorial Correspondence

Back to top